|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM153006145 |
| 003 |
DE-627 |
| 005 |
20231223063143.0 |
| 007 |
tu |
| 008 |
231223s2005 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0510.xml
|
| 035 |
|
|
|a (DE-627)NLM153006145
|
| 035 |
|
|
|a (NLM)15639643
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Scher, Jose U
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a 15d-PGJ2
|b the anti-inflammatory prostaglandin?
|
| 264 |
|
1 |
|c 2005
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 08.03.2005
|
| 500 |
|
|
|a Date Revised 08.01.2021
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a 15-Deoxy-Delta-12,14-prostaglandin J2 (15d-PGJ2) is the most recently discovered prostaglandin. This cyclopentanone, the dehydration end product of PGD2, differs from other prostaglandins in several respects. There is no specific prostaglandin synthase (PGS) leading to 15d-PGJ2 production and no specific 15d-PGJ2 receptor has been identified to date. Instead, 15d-PGJ2 has been shown to act via PGD2 receptors (DP1 and DP2) and through interaction with intracellular targets. In particular, 15d-PGJ2 is recognized as the endogenous ligand for the intranuclear receptor PPARgamma. This property is responsible for many of the 15d-PGJ2 anti-inflammatory functions. In this review, we summarize the current understanding of 15d-PGJ2 synthesis, biology and main effects both in molecular physiology and pathological states
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
7 |
|a 15-deoxyprostaglandin J2
|2 NLM
|
| 650 |
|
7 |
|a NF-kappa B
|2 NLM
|
| 650 |
|
7 |
|a PPAR gamma
|2 NLM
|
| 650 |
|
7 |
|a Prostaglandin-Endoperoxide Synthases
|2 NLM
|
| 650 |
|
7 |
|a EC 1.14.99.1
|2 NLM
|
| 650 |
|
7 |
|a Prostaglandin D2
|2 NLM
|
| 650 |
|
7 |
|a RXY07S6CZ2
|2 NLM
|
| 700 |
1 |
|
|a Pillinger, Michael H
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 114(2005), 2 vom: 10. Feb., Seite 100-9
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:114
|g year:2005
|g number:2
|g day:10
|g month:02
|g pages:100-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 114
|j 2005
|e 2
|b 10
|c 02
|h 100-9
|